Clinical effect of traditional Chinese medicine wax therapy guided by the midnight-noon ebb-flow theory on active period rheumatoid arthritis patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064866

Enrollment

Unknown

Registered

2022-10-20

Start date

2022-10-24

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Control group:Western medicine treatment and care following international guidelines

Experimental group 1:Western medicine treatment and care following international guidelines + traditional Chinese medicine wax therapy at 5:00~7:00 pm

Experimental group 2:Western medicine treatment and care following international guidelines + traditional Chinese medicine wax therapy outside the time of 5:00~7:00 pm

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 20 to 80 years, no gender limit; 2. Meet the 2009 ACR/EULAR western medicine diagnostic criteria for RA and the disease is active; 3. Meet the diagnostic criteria of TCM syndromes, and the TCM syndrome types are cold-dampness obstruction type or liver-kidney deficiency type; 4. The patient agrees to receive traditional Chinese medicine wax therapy and signs the informed consent form for clinical research; 5. Clear consciousness, stable vital signs, primary school education or above, good expression and communication skills.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating patients; 2. Those with serious damage to the heart, liver, kidney and other systems; 3. Those who have adverse reactions to the traditional Chinese medicines and medical paraffin used in this research; 4. Those with skin ulceration, high fever, weak constitution, and with sensory disturbance of warmth; 5. Those who have a bleeding tendency and bleeding diseases, or have other contraindications to wax therapy; 6. Superimpose other types of rheumatic immune diseases, such as ankylosing spondylitis, systemic lupus erythematosus, etc.

Design outcomes

Primary

Measure	Time frame
Disease Activity Score 28;	—

Secondary

Measure	Time frame
Health Assessment Questionnaire;Visual Analogue Score for Pain;TCM Syndrome Grading Quantitative Score;Erythrocyte Sedimentation Rate;C-Reactive Protein;Interleukin-6;Tumor Necrosis Factor-a;	—

Countries

China

Contacts

Public ContactZheng Huifang

The First Affiliated Hospital of Zhejiang Chinese Medical University

202011114111003@zcmu.edu.cn+86 17756900129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026